INNOVACAP vs WOCKPHARMA: Stock Comparison

INNOVA CAPTAB vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. INNOVA CAPTAB shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INNOVACAP leads 10; WOCKPHARMA leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INNOVACAPWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹6,760 Cr
₹33,908 Cr
P/E RatioINNOVACAP has the lower reading
41.02x
75.68x
P/B RatioINNOVACAP has the lower reading
5.93x
6.27x
EPSWOCKPHARMA has the higher reading
₹5.6
₹6.58
Book ValueContext only
₹188.99
₹325
Dividend YieldINNOVACAP has the higher reading
0.17%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹6,760 Cr
P/E Ratio
INNOVACAP has a lower P/E
41.02x vs 75.68x
P/B Ratio
INNOVACAP has a lower P/B
5.93x vs 6.27x
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹5.6
Dividend Yield
INNOVACAP has a higher dividend yield
0.17% vs 0%
Revenue Growth (TTM YoY)
INNOVACAP has faster revenue growth
42.3% vs 26%
EPS Growth (TTM YoY)
INNOVACAP has faster EPS growth
28.6% vs 0%
Qtr Sales Growth
INNOVACAP has stronger quarterly sales growth
-14.95% vs -39.61%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINNOVACAPWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINNOVACAPWOCKPHARMA
Live Price₹1,175.4₹2,088.7
Day Change4.44%7.08%
Volume3.22 L35.58 L
52-Week High₹1,155.8₹2,422.3
52-Week Low₹622₹1,086.7
Distance from 52W High1.7%-13.77%

Valuation

MetricINNOVACAPWOCKPHARMA
Market Cap₹6,760 Cr₹33,908 Cr
P/E Ratio41.02x75.68x
P/B Ratio5.93x6.27x
EPS₹5.6₹6.58
Book Value₹188.99₹325
Dividend Yield0.17%0%

Growth

MetricINNOVACAPWOCKPHARMA
Revenue Growth (TTM YoY)42.3%26%
EPS Growth (TTM YoY)28.6%0%
Qtr Sales Growth-14.95%-39.61%
Qtr Profit Growth-27.34%0%

Profitability & Leverage

MetricINNOVACAPWOCKPHARMA
ROE12.92%10.28%
ROCE10.73%10.37%
Net Margin8.65%3.3%
Operating Margin12.59%28.35%
Debt to Equity0.32x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINNOVACAPWOCKPHARMA
Promoter Holding50.9%49.08%
FII Holding0.34% 0.11 pp7.22% 0.13 pp
DII Holding19.92% 0.22 pp9.24% 1.72 pp
Public Holding28.84% 0.11 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INNOVA CAPTAB and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.